Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

tildrakizumab

- PMLiVE

Takeda’s zasocitinib demonstrates positive results in plaque psoriasis

Around 64 million people worldwide live with psoriasis

- PMLiVE

Global Healthy Living Foundation and Medscape Education Join Forces to Bridge the Gap Between Patients and Providers with Immunology Education

UPPER NYACK, N.Y.--(BUSINESS WIRE)--The Global Healthy Living Foundation (GHLF) today announced a new partnership with Medscape Education to advance patient-centered innovation within the Immunology Learning Nexus (Nexus), Medscape’s flagship multi-year...

Medscape Education

- PMLiVE

Johnson & Johnson seeks first EMA approval for icotrokinra for plaque psoriasis

Icotrokinra is a first-in-class, once-daily tablet for moderate-to-severe plaque psoriasis

- PMLiVE

Almirall and Absci expand AI dermatological drug discovery partnership

The alliance has already led to the delivery of functional antibody leads against a difficult-to-drug target

- PMLiVE

Apogee Therapeutics’ atopic dermatitis candidate shows promise in phase 2 study

The inflammatory skin condition affects over 26 million people in the US

- PMLiVE

Honoring the Legacy of Dr. Robert Sidbury, MD, MPH

We are deeply saddened by the recent passing of Dr. Robert Sidbury. Dr. Sidbury was a visionary in pediatric dermatology whose dedication to advancing patient care inspired clinicians, researchers, and...

Medscape Education

- PMLiVE

LEO Pharma gains access to Boehringer’s skin disease drug for €90m upfront

Spevigo is already approved in over 40 countries to treat generalised pustular psoriasis

- PMLiVE

Dermaliq and DEBRA partner to advance epidermolysis bullosa drug delivery

Approximately 500,000 people worldwide are affected by the rare genetic skin disorders

- PMLiVE

J&J/Protagonist’s icotrokinra shows promise in difficult-to-treat plaque psoriasis

An estimated eight million people in the US are living with the immune-mediated skin disease

- PMLiVE

LEO Pharma and the Parker Institute join forces to advance dermatology research

The alliance will aim to discover molecules that could be incorporated into wider pharmaceutical research

- PMLiVE

LEO and Reig Jofre partner to improve access to psoriasis therapy in Europe

Approximately 125 million people worldwide are affected by some form of the inflammatory condition

- PMLiVE

Almirall hosts Skin Academy to advance skin science and dermatology treatments

The conference will cover actinic keratosis, psoriasis, atopic dermatitis and other skin diseases

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links